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Thesis Summary 
 Phenylalanine hydroxylase deficiency is a rare genetic disorder in which patients are 
unable to metabolize the amino acid phenylalanine. Phenylalanine accumulates in the body as a 
consequence of the enzymatic deficiency. If the patient’s levels of phenylalanine are too high, 
there are many negative consequences. Pediatric patients may even experience mental 
abnormalities and deficiencies as a consequence of phenylalanine hydroxylase deficiency.  
 A pharmabiotic prototype has been created to treat phenylalanine hydroxylase deficiency 
in which the human enzyme phenylalanine hydroxylase is expressed by a safe, nonpathogenic 
bacteria. The modified bacteria will be formulated into a yogurt or capsule for oral 
administration. The bacteria will then express the enzyme in the body and replace the deficient 
phenylalanine hydroxylase enzyme, preventing the negative consequences of phenylalanine 
hydroxylase deficiency. This technology is patent pending.   
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Abstract 
Phenylketonuria, now known as phenylalanine hydroxylase (PAH) deficiency, is a 
genetic disorder of metabolism affecting approximately one in every 15,000 infants born in the 
United States. Patients have nonfunctional PAH enzyme secondary to one or more genetic 
mutations. The enzyme deficit results in destructive supraphysiologic blood phenylalanine levels 
upon consumption of the essential dietary amino acid phenylalanine. Current standards of care 
mitigate signs and symptoms of the disorder, but do not approach a cure. The methods for 
creating a prototype pharmabiotic as an innovative treatment strategy for PAH deficiency are 
described herein. 
DNA molecular cloning techniques were utilized to engineer a novel plasmid termed 
LiLi5, which was subsequently transformed into Lactobacillus helveticus. A cDNA for human 
PAH was amplified and inserted into a gram-neutral shuttle vector to create LiLi5, the bacterial 
plasmid which induces the expression of human phenylalanine hydroxylase. The LiLi5 plasmid 
was confirmed by restriction enzyme digest and sequencing of the cDNA insert. Successful 
transformation of LiLi5 into Lactobacillus helveticus generated a novel strain of Lactobacillus, 
which was christened “HELin”. PCR-based detection confirmed the presence of the human PAH 
cDNA in HELin. 
Phenylalanine hydroxylase deficiency is a debilitating disorder causing somatic, 
psychosocial, and financial distress for patients and their families. Current treatment strategies do 
not adequately address the decreased quality of life experienced by the associated patient 
population. Lactobacillus helveticus is a GRAS gram-positive bacterial species commonly 
formulated in commercially marketed probiotics. The novel strain of Lactobacillus expressing 
human phenylalanine hydroxylase that has been named ‘HELin’ is proposed to be formulated 
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into a pharmabiotic for testing as a new treatment for phenylalanine hydroxylase deficiency. 
Patent pending. 
Introduction 
Phenylalanine Hydroxylase Deficiency  
Phenylketonuria, now known as phenylalanine hydroxylase deficiency, is the textbook 
example of an incurable, lifelong metabolic disorder. Phenylalanine hydroxylase deficiency is 
primarily managed by strict dietary avoidance of phenylalanine. However, the psychosocial, 
physical, and financial ramifications of the disorder necessitate that treatments extending beyond 
the current standards of care be explored. Concomitantly, the human microbiome is one of the 
most rapidly advancing fields of research today. As academic and industrial research into the 
microbiome continues to produce various biome-altering formulations, it is inevitable that 
numerous applications will be discovered for such products. Here, the argument is made that it is 
plausible to both create and market a pharmabiotic for the management of phenylalanine 
hydroxylase deficiency.  
Phenylalanine hydroxylase deficiency is an inborn genetic error of metabolism. An 
intrinsically hepatic enzyme, phenylalanine hydroxylase is responsible for the production of 
tyrosine from the essential dietary amino acid phenylalanine. This process reduces plasma levels 
of phenylalanine. In cases of phenylketonuria, the enzyme is either nonfunctional or partially 
functional, secondary to a mutation in the PAH gene. Deficient expression of phenylalanine 
hydroxylase results in 
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supraphysiologic plasma levels of phenylalanine upon consumption of foods containing 
phenylalanine.  
 
Phenylalanine is present in dietary sources of protein such as fish, meat, nuts and eggs. 
Though autosomal recessive, phenylalanine hydroxylase deficiency affects 1 of every 15,000 
infants born in the United States. Diagnosis is made primarily from plasma screenings of 
newborns. Such screenings were made mandatory in the United States in the 1960’s. 
Hyperphenylalaninemia is diagnosed when untreated blood levels of phenylalanine are greater 
than the population norm of 60 μmol/liter, but less than the 1.2 mmol/liter diagnostic of classical 
phenylketonuria. Untreated classical phenylketonuria is associated with the most severe 
manifestations of the metabolic disorder.1 2  
Hyperphenylalaninemia causes significant clinical effects, including mental and 
psychosocial developmental delays. Psychotic symptoms, aggression, and autistic-type behaviors 
are reported in untreated patients. Depression and anxiety are frequently reported, even among 
patients who have maintained treatment for years. Lack of social awareness is also common 
among both treated and untreated patients. Several mechanisms for the psychiatric and 
neurotoxic effects of hyperphenylalaninemia have been suggested, including the induction of 
myelin abnormalities, the physical obstruction of amino acid transporters throughout the blood 
brain barrier by phenylalanine, and disturbances in neurotransmitter pathways. These biological 
mechanisms result in variable psychological effects, usually manifested in a direct positive, 
linear relationship to blood phenylalanine levels. It is also hypothesized that the stress of 
Image 1 Phenylalanine hydroxylase converts the amino acid phenylalanine to tyrosine. 
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maintaining a strict phenylalanine-limited diet for the entirety of the patient’s lifetime may 
contribute to the noted psychological disturbances.3 
Hyperphenylalaninemia causes physical as well as psychological consequence. Bone 
mineral density is negatively affected in patients with phenylalanine hydroxylase deficiency.4 
Concerns have been also expressed for the increased incidence of overweight noted among 
adolescent patients with PAH deficiency.5 Interestingly, muscle mass seems to be properly 
maintained among patients with appropriate intake. Anecdotal reports of spastic paraplegia in 
unmanaged patients have been recorded. Of less clinical significance, but still of note, patients 
with untreated phenylalanine hydroxylase deficiency are described as having a strong 
“distinctive musty odor”.6 
The 2014 American College of Medical Genetics clinical practice guidelines emphasize 
that once phenylalanine hydroxylase deficiency has been diagnosed, it is imperative for 
treatment to begin immediately, with an attempt to reach goal blood phenylalanine levels within 
two weeks of life. Disappointingly, the backbone of clinical treatment for phenylalanine 
hydroxylase deficiency remains dietary restriction of phenylalanine.7 For most patients, simply 
choosing to avoid foods rich in phenylalanine is not enough to prevent the consequences of 
hyperphenylalaninemia and may instead induce the negative physical consequences of 
inadequate protein consumption. This first tier of treatment alone may not be appropriate in such 
cases. Instead, medical formulas that contain sufficient levels of all other dietary amino acids, 
but restricted phenylalanine, must be utilized as a primary food source, or highly relied upon 
secondary to a strict diet, to support growth. It is acknowledged that medical foods improve the 
variety of dietary options for patients with phenylalanine hydroxylase deficiency, but at an 
increased cost. Certain medical foods are often not covered by insurance and therefore increase 
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the financial burden of PAH deficiency. Patients have also described the medical foods as having 
the distinct taste of bile, which, while highly unpleasant to the layperson, is imagined to be 
nearly unbearable in the pregnant and pediatric populations.8 The social and emotional 
consequences of having a diet restricted to medical formulas alone must also not be overlooked.9 
Certain mutations in the gene encoding phenylalanine hydroxylase yield an enzymatic 
deficiency that is termed tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. 
In such cases, the administration of certain pterin cofactors will increase the metabolism of 
phenylalanine to tyrosine by phenylalanine hydroxylase. In 2007, Kuvan (sapropterin 
dihydrochloride) tablets and oral solution were approved by the FDA for use in the United 
States. Kuvan is indicated to reduce blood phenylalanine levels in conjunction with a 
phenylalanine restricted diet. However, studies have shown that the medication has no effect in 
patients who are non-responders.10 In June of 2018, the price of Kuvan was listed as $48.00 per 
tablet in non-contract and non-340B pricing by McKesson, a third-party distributer of the 
product. Investigations into large neutral amino acid (LNAA) supplementation as adjacent or 
alternative therapy have been undertaken, however, strict treatment guidelines have not been 
established and results in the scientific literature are underwhelming.11 LNAAs are treated as 
medical foods in the United States and are not recommended in younger patients due to the lack 
of evidence for safety.  
The management of phenylalanine hydroxylase deficiency poses a challenge not only for 
healthcare providers, but also for the families of those affected. A 2016 cross-sectional study 
performed in the United Kingdom reported that a median of 19 hours per week was spent by 
caretakers in activities related to the management of the disorder.9 According to the National 
PKU Alliance of the United States, treatment of phenylalanine hydroxylase deficiency costs 
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approximately $15,000 per year. Third party payer support is payer-specific and variable. The 
alliance also states that inpatient care for a patient who has sustained neurological damage 
secondary to PAH deficiency may cost upwards of $200,000 per year. It can be inferred that the 
burden of this cost would fall upon the US healthcare system.  
The temporal, emotional and financial burden of phenylalanine hydroxylase deficiency 
demand that a more effective or novel treatment methodology be developed to improve the 
quality of life for patients and their families. The current clinical practice guidelines emphasize 
that “any interventions, including medications, or combination of therapies that help to achieve 
that goal [of lowered blood phenylalanine levels] in an individual, without other negative 
consequences, should be considered appropriate therapy”.7 Leveraging the human microbiome 
could provide a breakthrough treatment approach to the management of phenylalanine 
hydroxylase deficiency.  
The Microbiome 
 The National Institute of Health launched the first phase of the Human Microbiome 
Project (HMP1) in 2008 with the goal of characterizing the cohabitants of the human body.  Not 
only did the project initiators attempt to create an accessible list of microorganisms 
acknowledged as “normal” through 16S RNA sequencing of samples from hundreds of human 
donors, but also to generate a foundational understanding of the metabolic interplays resulting 
from a human-contained ecosystem.12  HMP1 was birthed conceptually from the confounding 
deficit in human protein-generating genes sequenced by the preceding Human Genome Project. 
It was concluded that the portion of protein-producing genetic information sequenced during 
HMP1 which was determined to be inhuman did not simply materialize and was likely the result 
of the inhabitants of the human microbiome. Thus, intensive investigation into the metabolic 
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consequences of the human microbiome began.13 HMP1 sparked a nation-wide interest in the 
human microbiome, fueled by the intrinsic and often desperate desire of the scientific community 
to understand, prevent, and treat human disease. 
Joshua Lederberg, a molecular biologist, coined the term microbiome “to signify the 
ecological community of commensal, symbiotic, and pathogenic microorganisms that literally 
share our body space”.  The community that Lederberg defined is not only comprised of bacterial 
cells, but “bacteria, bacteriophage, fungi, protozoa and viruses”.  It is acknowledged that the 
number of microbial cells outnumbers those of human cells by a factor of at least 10. In 2009, 
only one year after the launch of the first phase of the Human Microbiome Project, a marker 
paper published by the HMP Working Group acknowledged investigations into the implication 
of the microbiome in the pathophysiology of psoriasis, pediatric febrile illness, obesity, bacterial 
vaginosis, and cancers of the gastrointestinal tract.14 By 2011, the list had expanded to include 
preliminary investigation into the role of the microbiome in Crohn’s disease, ulcerative colitis, 
pediatric inflammatory bowel syndrome, neonatal necrotizing enterocolitis, and gastroesophageal 
reflux disease.15 In 2013, Phase 2 of the Human Microbiome Project began, with intense focus 
on the role of the microbiome in human disease.  
 The behavior of the human microbiome is governed by many of the same 
principles as large-scale ecology. Each person’s individual microbiome may be considered a 
complete and separate ecosystem. The development of the human microbiome begins 
immediately after birth, when a neonate is colonized with pioneer bacterial colonies from the 
mother. These vertically transferred pioneer colonies are most frequently documented as 
Lactobacilli.16 As the neonate ages, the microbial ecosystem forms, with adult-like colonization 
theorized to be completed near age three.17 As a general principal, a diverse microbial population 
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is considered the most physiologically beneficial to the host, as it potentiates species resilience, 
which is known to promote human homeostasis. However, certain environmental factors can 
induce extinction or species imbalance. Dietary changes, consumption of alcohol, natural aging, 
the use of antimicrobial agents and pathophysiology are well known to cause species variation in 
the microbiome. 
Aside from natural processes, industrialized products have been developed and 
introduced to the market with claims of altering the microbiome for improved wellbeing. 
Probiotics are marketed as formulations of live bacteria that are administered to the patient. 
Prebiotics are substances that may or may not be digested which yield a favorable environment 
for microbes of choice. Synbiotics are commonly accepted as combinations of the two 
aforementioned products. As the number of such quasi-pharmaceutical products grows, so does 
the clinical interest and scrutiny of such treatments. Clinical reviews have acknowledged that 
probiotics certainly play a role in treating disorders of the gastrointestinal tract and are useful in 
the maintenance of general wellbeing.18 Ongoing research is validating the tentative use of 
microbiome-altering products for metabolic disorders and treatment of recurrent Clostridium 
difficile infections.19 Recent research even hints at the possibility of the psychological benefits of 
probiotics, exploiting the gut-brain axis.20 
 Extending beyond probiotics, prebiotics, and synbiotics is the concept of the 
pharmabiotic. Pharmabiotics have been defined as “bacterial cells of human origin, or their 
products, with a proven pharmacological role in health or disease”.21 It can be argued that 
genetically modified organisms isolated from the microbiota would be classified as 
pharmabiotics, especially in the case of a genetically modified organism producing a 
physiologically beneficial protein in vivo. Recent research has explored the potential for 
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application of pharmabiotic treatment in cases of hyperammonemia, even going so far as to 
claim that the pharmabiotic approach to this disease state is ideal.22 If properly developed, the 
therapeutic applications secondary to synthetic alterations in the microbiome are limited only by 
the threshold of imagination. Here, in contrast to hyperammonemia, we discuss the development 
of a pharmabiotic for the treatment of phenylalanine hydroxylase deficiency.  
 The model organism for creation of a pharmabiotic should exhibit several 
essential characteristics. Most obviously, the organism should be non-pathogenic, clearly 
taxonomically identifiable, and commercially available. The organism would ideally be 
amenable to genetic manipulation, but retain genetic stability after insertion of a plasmid or an 
induced chromosomal integration event. Subsequent generational identicality, the epitome of 
genetic stability, would be desired. In instances when a plasmid is inserted into a bacterium, it is 
desirable for the antibiotic resistance gene used for laboratory selection processes to be excised 
before in-vivo administration, especially if the resistance gene were transferable to other 
organisms, to avoid potential generation of a multi-drug resistant organism. There may be a place 
in therapy for a pharmabiotic retaining antibiotic resistance, but this concept will be further 
explored in the discussion. Finally, the model organism would need to retain viability in an 
appropriate dosage form, such as a yogurt, slurry, or capsule. Once administered, the 
pharmabiotic organism would need to be resistant to bile acids and proliferate near or adhere to 
epithelial tissues in the gastrointestinal tract. The location of adherence would also play a large 
role in the purported efficacy of pro- or pharmabiotics. The small intestine is the site of 
reabsorption for amino acids and would be preferred for the location of action of a 
pharmabiotic.23 After much comparison, it was determined that a specific strain of Lactobacillus, 
Lactobacillus helveticus, was extremely qualified for formulation into a pharmabiotic.   
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Lactobacillus helveticus, belonging to the family of lactic acid bacteria, has historically 
been utilized in the production of Swiss cheese and is present in fermented milk. The genus 
Lactobacillus has been given “Generally Recognized as Safe” status and L. helveticus 
particularly has been given the designation of a “Qualified Presumption of Safety”. It is 
generally accepted as a probiotic strain and is formulated into commercially available products. 
The full genome sequence of L. helveticus has been documented.24 Genetically modified L. 
helveticus has been documented to survive passage through the human gastrointestinal tract, 
suggesting bile resistance.25  In vitro studies have demonstrated the ability of L. helveticus to co-
aggregate efficiently with E. coli and adhere to epithelial cells.26 Each of these qualities lend 
themselves to the theory that L. helveticus could be genetically manipulated and subsequently 
formulated into a pharmabiotic for the treatment of phenylalanine hydroxylase deficiency. A 
detailed description of the creation of such a pharmabiotic is provided in the Materials and 
Methods. 
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Plasmid Map 
 
 
 
 
 
Plasmid/Fragment Size 
pCMV6-XL4 4.7 kb 
pTRKH2 6.7 kb 
Insert containing PAH cDNA 2.3 kb 
PAH cDNA 1.3 kb 
LiLi5 8 kb 
Model 1- Creation of the Novel Plasmid LiLi5 
Commercial plasmid PCMV6-XL4 (navy blue) was cut with Not1 restriction enzyme (scissors) to release an 
insert containing human PAH cDNA (orange). Primers specific to PAH and introducing Sac1 and Sal1 cut 
sites (blue boxed arrows) were used to PCR amplify the PAH cDNA insert, which was later purified (light 
blue). pTRKH2 (green), a second commercial plasmid, was cut with restriction enzymes Sac1 and Sal1 
(scissors). A ligation reaction (paper clips) was performed between pre-cut pTRKH2 and purified PAH 
cDNA to create a novel plasmid, LiLi5 (green and light blue). 
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Materials and Methods  
 
Bacterial Strains 
Escherichia coli was utilized to amplify DNA for manipulation. Specifically, stock 
strains of electrocompetent Escherichia coli cells were obtained from Lucigen (Middleton, WI). 
The plasmid pCMV6-XL4 containing the cDNA for human phenylalanine hydroxylase (PAH) 
was obtained from Origene (Rockville, MD). pCMV6-XL4 was introduced into E. coli by the 
preset E. coli protocol of the BioRad Gene Pulser Xcell Electroporation System. E. coli 
containing the plasmid pTRKH2 were purchased from Addgene (Cambridge, MA) and 
proliferated. pTRKH2 is a well-known shuttle vector that can be propagated in both E. coli and 
gram-positive bacteria such as Lactobacillus helveticus. Wild-type L. helveticus strain number 
#15009 were purchased from ATCC (Manassas, VA).  
 E. coli were grown aerobically, agitated at speeds between 180 and 200 rpm, angled, 
and incubated overnight at 37 °C. TB broth or ‘Terrific Broth’, a commonly used bacterial media, 
was used for growth in most instances, although no substantial variations were noted between the 
growth of E. coli in either LB (Luria-Bertani) or TB broth. MRS broth (deMan, Rogosa and 
Sharpe), a bacterial growth media specifically designed to provide luxuriant growth conditions for 
Lactobacillus, was used for propagation of L. helveticus, which was grown in anaerobic conditions 
without shaking at 37 °C. L. helveticus was allowed 48 hours for growth on plates and 72 hours 
for growth in liquid culture. Liquid cultures of L. helveticus were morphologically distinct from 
those of E. coli, with growth appearing as settled flakes and having the gross appearance of 
dandruff. As evidenced by the image below, Lactobacillus helveticus grows and settles in the form 
of a pellet on the bottom of any container containing liquid media, leaving the upper media clear. 
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This is in contrast to E. coli, which often grew equally distributed throughout liquid media, creating 
a cloudy appearance.   
 
Image 2 Early stages of Lactobacillus helveticus growth as indicated by the arrow. 
Plasmid Production 
The pCMV6-XL4 and pTRKH2 plasmids were amplified by growing E. coli harboring 
the respective plasmids in TB plus appropriate antibiotic for selection. E. coli containing 
pCMV6-XL4 were propagated in 1-3 milliliters of liquid culture after loop inoculation of TB 
media containing 50 μg/ml ampicillin and incubated overnight at 37 °C with angled shaking at 
180 rpm. Liquid cultures were grown for no less than sixteen hours. The gram-positive shuttle 
vector pTRKH2 was amplified by propagating E. coli as above but with the use of 150 μg/mL 
erythromycin for selection. Both plasmids were isolated from E. coli using a Qiagen MiniPrep 
plasmid extraction kit and following the manufacturer’s protocol.  
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Determination of Sample DNA Concentration    
All sample DNA concentrations were determined in 2 μL aliquots via use of a NanoDrop 
Spectrophotometer by ThermoFisher Scientific, model 2000. Measurements were performed per 
manufacturer standards, including the use of appropriate blank solutions. 
Gel Electrophoresis, Restriction Enzyme Digests, Gel-Based Isolation of DNA Fragments 
All gel electrophoresis was carried out on 0.8% agarose gels for identification of correct 
plasmid size and estimation of quality and purity. Restriction enzymes Not1, Sac1 (High Fidelity) 
and Sal1 were obtained from New England Biolabs (Ipswich, MA). Digests were carried out per 
manufacturer instructions. To prepare for ligation of the PAH cDNA into the pTRKH2 backbone, 
the DNA samples were each incubated with both Sac1 and Sal1, followed by separate gel 
electrophoresis. The plugs of agarose gel containing each DNA fragment were excised from the 
gel with a razor blade. Digested DNA was purified from the agarose using a Thermo Scientific 
GeneJET Gel Extraction kit #K0691.  
Polymerase Chain Reaction (PCR) 
PCR of the cDNA for phenylalanine hydroxylase was performed with 12.5 μL of 
Mastermix, 1.25 μL of forward and reverse primers at 10 μM each, 3 μL of the isolated Not1 
fragment from pCMV6-XL4 at a concentration of 3 ng/μL and 7 μL of sterile DNase and RNase-
free water.  Standard PCR reactions are performed in a thermocycler and commonly involve an 
initial activation step, followed by three-step cycling of denaturation at 94 °C, annealing at 
primer-specific temperatures, and extension at 72 °C for Taq polymerase. An annealing 
temperature of 57 °C was used for the primers designed for human PAH. The forward primer 
was:  
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5’-ATGTCCACTGCGGTCCTGGAAAACCCAGGCTTG. 
The reverse primer was: 
5’-TTACTTTATTTTCTGGAGGGCACTGCAAAGGATTCC. 
A second PCR reaction was performed as above to introduce Sac1 and Sal1 cut sites on 
the PAH isolate with a concentration of 3 ng/μL. The forward primer, including the additional 
sequence of the Sac1 cut site, was: 
5’-CGCGGAGCTCATGTCCACTGCGGTCCTGGAAAACCCAGGCTTG  
and the reverse primer, containing the Sal1 cut site was: 
5’-GCGCGTCGACTTACTTTATTTTCTGGAGGGCACTGCAAAGGATTCC.   
Ligation 
DNA ligase was obtained from Lucigen (Middleton, WI). The ligation was performed per 
manufacturer instructions between the double-digested products of the shuttle vector pTRKH2 
and the PAH cDNA fragment which was amplified by PCR using primers to introduce 
appropriate the enzyme cut sites. 4 μL of digested pTRKH2, 7 μL of the digested PAH fragment, 
1 μL of DNA ligase, and 1.5 μL each of 10x ligation buffer and DNAse and RNAse-free water 
were placed together in a microcentrifuge tube and incubated at room temperature for five 
minutes. The tube was then incubated in a water bath at 70 °C for 15 minutes and then 
centrifuged for one minute at 10,000 rpm. 
Electroporation of E. coli 
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Electroporation of E. coli was performed with a BioRad Gene Pulser Xcell 
Electroporation System and a preset protocol for E. coli. The pre-set protocol included 1800 V,  
25 μF, 200 Ω, and a 1 mm cuvette.  
Electroporation of Lactobacillus helveticus 
Preparation of electrocompetent Lactobacillus helveticus followed the protocol described 
by Welker (doi: 10.1093/femsle/fnu033). For the electroporation of the prepared Lactobacillus 
helveticus, 100 μL of electrocompetent cell suspension was loaded into electroporation 
microcuvettes followed by 200 ng of sample plasmid DNA. In separate cuvettes, pTRKH2, LiLi5, 
and a control with no plasmid were subjected to an electroporation in a BioRAD GenePulser 
XCell under the following conditions: 25 μF capacitance, 400 Ω resistance, and 2000 V. After 
retrieval from the cuvette, 100 μL of each cell suspension was then placed in 900 μL of MRS 
recovery media and incubated for 4 hours at 37 °C. The entire volume of the incubated cell 
suspensions was then transferred into 10 mL of MRS broth containing 0.5 μ/mL erythromycin for 
antibiotic selection in liquid culture. A control of wild type Lactobacillus helveticus lacking 
plasmid was also incubated with 0.5 μg/mL erythromycin to confirm positive selection in the 
presence of plasmids containing antibiotic resistance.  
Colorimetric Analysis of Media Tyrosine Content 
 It was hypothesized that if fully functional phenylalanine hydroxylase enzyme were 
expressed from the LiLi5 plasmid in Lactobacillus, the PAH enzyme would metabolize the 
phenylalanine in the media to tyrosine and levels of tyrosine in the MRS broth in which 
Lactobacillus were growing would rise in a detectable fashion. It was also hypothesized that this 
increase in tyrosine levels in the media would be detectable by colorimetric tyrosine assay kit.  
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1.5 mL aliquots of MRS broth with 0.5 μg/mL erythromycin for selection were loop 
inoculated separately with Lactobacillus helveticus expressing pTRKH2 and Lactobacillus 
helveticus expressing novel plasmid LiLI5. A 1.5 mL aliquot of plain MRS broth was carried 
through the experiment as a control for baseline levels of tyrosine media in MRS broth. Samples 
were incubated statically at 37 °C for 48 hours and then the optical density (OD600) was taken for 
the samples containing Lactobacillus. The samples were adjusted for optical density via a 
dilution factor and three additional aliquots of 1.5 mL of MRS broth with 0.5 μg/mL 
erythromycin were inoculated separately with HELin and L. helveticus containing pTRKH2. 
Samples were again incubated statically at 37 °C for 36, 48, and 60 hours, respectively. The 
Tyrosine Colorimetric Assay Kit #K573-100 was purchased from BioVision (Milpitas, CA) and 
performed per manufacturer instructions. MRS broth at each timepoint was substituted for 
traditional serum or urine sampling. Prior to removing the supernatant for sampling, samples 
were centrifuged for sufficient time to produce a bacterial pellet. ~100 μL of supernatant was 
then deproteinized using a 10 kDa spin column and centrifuged again at 10,000 x g for 10 
minutes at 4°C. 
A 96 well plate was loaded with samples of each sample MRS supernatant at each 
timepoint following kit instructions. A plate reader was utilized to report out sample absorbance 
values. The Colorimetric Assay Kit utilizes the enzymatic oxidation of tyrosine, which produces 
a stable signal of OD 492 nm. A standard tyrosine curve was produced per kit instructions (see 
Figure 10). The equation y = 0.0048x + 0.0154 (where Y represents absorbance at OD 492 nm 
and X represents nanomolar tyrosine) was generated from the tyrosine standard curve. This 
equation was used to approximate nanomolar tyrosine content in the various MRS samples and 
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graphed as to display the change over time. Results from the plate reading are displayed in 
Figure 11. 
Western Blotting  
Western blots were performed by Jacob Massey, PhD candidate, using standard 
laboratory protocols and anti-PAH goat antibody purchased from Fisher Scientific (Pittsburg, 
PA). Samples were run at 140 V for 50 minutes in a 4-20% gradient pre-cast gel (Bio-rad 
4561093) in homemade SDS-Page buffer. The gel was transferred onto a PVDF membrane at 
100 V for 100 minutes at 4 °C.  The membrane was blocked in 5% blocking milk in PBST for 
one hour prior to overnight incubation with goat anti-PAH primary antibody (Novus NBP1-
52084, 1:500).  After primary incubation, the secondary rabbit anti-goat-HRP antibody (Fisher 
PI-31402 1:2000) was incubated at room temperature for 1 hour. The HRP was activated using 
the ECL western blotting substrate (ThermoFisher 32106) prior to being imaged using a Bio-Rad 
ChemiDoc Imaging System. 
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Results  
 The intent of the project was to create a modified strain of Lactobacillus helveticus, 
producing the human enzyme phenylalanine hydroxylase. The first step in the process was to 
isolate the plasmid containing the cDNA for the PAH enzyme, pCMV6-XL4. The far-left lane of 
Figure 1 shows 5 μL of pCMV6-XL4 DNA loaded onto a 0.8% agarose gel. The plasmid was 
identified by size comparison to a BioRad Log 2 Ladder, lane 3 of Figure 1. This figure 
demonstrates that pCMV6-XL4 was successfully propagated in and subsequently isolated from 
E. coli. The appearance of three bands shows that the plasmid was visualized in three 
predominant forms: open circular, linear and supercoiled.  
 
Figure 1 Commercial plasmid pCMV6-XL4 containing human PAH cDNA was isolated from E. coli 
following standard plasmid mini-prep protocol. The left lane labeled ‘pCMV6’ shows the plasmid DNA 
isolated from E. coli.  The right lane labeled ‘ladder’ shows the BioRad Log2 ladder with different 
molecular weight bands labeled by their size.   
 
6 kb 
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The pCMV6-XL4 plasmid was next digested with the restriction enzyme Not1. The 
manufacturer’s stated size of pCMV6-XL4 backbone was 4.7 kb with a 2.3 kb insert containing 
the PAH cDNA. Not1 sites flank the PAH cDNA, thus Not1 digest removes the cDNA from the 
backbone. Figure 2 shows an agarose gel loaded with 40 μL of pCMV6-XL4 plasmid cut twice 
with Not1 in comparison to a log 2 ladder. This result confirms that a DNA fragment 
corresponding to the 2.3 kb fragment that contains the human PAH cDNA was successfully 
excised from the pCMV6-XL4 plasmid after Not1 digest. The 3 ng/μL yield of PAH cDNA 
necessitated that a polymerase chain reaction be performed to amplify the product. 
 
Figure 2 The PAH cDNA fragment was freed from plasmid pCVM6-XL4 via Not1 restriction enzyme 
digest, as demonstrated by the left lane labeled ‘PAH cDNA’. The right lane labeled ‘ladder’ shows the 
BioRad Log2 ladder with different molecular weight bands labeled by their size. The arrow indicates the 
fragment removed from the backbone. 
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Next, PCR was used to specifically amplify the human PAH cDNA from the 2.3 kb 
fragment excised from the pCMV6-XL4 plasmid. Lane 1 of Figure 3 shows the 2.3 kb fragment 
(labeled excerpt) released from digesting the PCMV6-XL4 plasmid with Not1 and purified by 
gel electrophoresis. Lane 2 demonstrates the result of PCR performed on the Not1-excised 
fragment in lane 1 using primers specific to human PAH cDNA, yielding a 1.3 kb product. This 
result confirms that the primers specific to human PAH cDNA amplified a 1.3 kb portion of 
cDNA within the 2.3 kb insert removed from the pCVM6-XL4 plasmid. No amplification was 
seen with the control PCR, confirming that the reaction was specific to amplification of human 
PAH cDNA with the primers used. An additional PCR was performed using the same conditions 
as above, but with the substitution of primers also containing Sac1 and Sal1 enzyme cut sites. 
Primers with additional flanking cut sites were used to provide compatible ends for subsequent 
ligation of the PAH cDNA into the pTRKH2 shuttle vector backbone.  
 Figure 4 demonstrates a gel run with 3 μL of  
Figure 3 The human PAH cDNA fragment was amplified via PCR. The far-left lane labeled ‘Excerpt’ 
shows the 2.3 kb PAH cDNA fragment removed from PCMV6-XL4 with Not1. The left lane labeled 
‘PAH’ shows the 1.3 kb PAH cDNA amplified via PCR. The ‘control’ lane demonstrates that the 
primers were specific to PAH as no superfluous amplification took place. The right ‘ladder’ lane 
exhibits the BioRad Log2 ladder with different molecular weight bands labeled by their size. 
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PAH cDNA after PCR amplification in the far-right lane using primers with the flanking enzyme 
cut sites.  
 
 
Figure 4 The PCR of the PAH cDNA was repeated with the use of primers to introduce Sac1 and Sal1 
cut sites, the result of which is pictured in the right lane labeled ‘PAH (Cut Sites)’. The left lane is another 
visualization of the BioRad Log2 ladder with different molecular weight bands labeled by their size. 
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The PCR product of PAH containing enzyme cut sites at the 5’- and 3’- ends was then 
subjected to a double restriction enzyme digest and loaded onto a gel to separate and purify the 
DNA fragment with ligatable ends. After electrophoresis, a small plug of agarose containing the 
DNA of interest was excised from the gel, and the DNA subsequently purified away from the 
agarose as described in Materials and Methods.  
pTRKH2 was also isolated from E. coli and subjected to gel electrophoresis to confirm 
successful extraction. The right lane of Figure 5 shows 5 μL of pTRKH2 DNA in comparison to a 
log 2 ladder. In preparation for ligation with the PAH cDNA fragment, pTRKH2 was double 
digested by Sac1 and Sal1 restriction enzymes, separated on a gel, and purified from the agarose 
plug as described above.  
Figure 5 The commercial plasmid pTRKH2 was isolated from E. coli via standard plasmid mini-prep 
protocol, as shown in the right lane labeled ‘pTRKH2 (Uncut)’. The middle lane labeled “Ladder” is a 
visualization of the BioRad Log2 ladder with different molecular weight bands labeled by their size.  
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  A ligation was then performed between the purified double-digest products of the shuttle 
vector pTRKH2 and the PAH cDNA PCR product with flanking enzyme cut sites.  
 The products of the ligation reactions were termed the “LiLi” series of plasmids. The 
LiLi plasmids were introduced into stock strains of E. coli via electroporation as described 
above. Original pTRKH2 plasmid and vehicle (no plasmid) also went through the electroporation 
protocol as controls. After electroporation, 15 and 150 μL aliquots of cells were plated on LB 
plates containing 150 μg/ml erythromycin and incubated for 15 hours at 37 °C. E. coli colony 
formation was noted for cells containing ligation products or pTRKH2, but not for E. coli 
lacking plasmid. Individual colonies from the pTRKH2-PAH ligation reactions were isolated and 
streaked out on a secondary plate and for overnight incubation. Colonies containing the LiLi 
series of plasmids were chosen to inoculate four tubes of 2 mL liquid LB media with 150 μg/ml 
erythromycin. A plasmid extraction was performed using the Qiagen MiniPrep plasmid 
extraction kit, yielding approximately 30 ng/μL of DNA per colony. Figure 6 compares the sizes 
of several extracted LiLi plasmids to a ladder and pTRKH2.  
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Figure 6 The LiLi series of plasmids were generated via ligation between commercial plasmid pTRKH2 
cut with Sac1 and Sal1 and human PAH cDNA amplified with added enzyme cut sites. Each individual 
colony in the series was given a name beginning with LiLi and then a sequential number. pTRKH2, as 
pictured in the far-right lane labeled ‘pTRKH2’ was used as a size reference to infer the success or failure 
of the ligation reaction. The LiLi series of plasmids are visualized separately in the lanes labeled ‘LiLi5, 
LiLi6’, etc. after extraction from E. coli. The lane labeled ‘Ladder’ is a visualization of the BioRad Log2 
ladder with different molecular weight bands labeled by their size. 
Ladder 
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As demonstrated by Figure 6, LiLi5, LiLi7, and LiLi3 are larger plasmids than pTRKH2, 
suggesting that they may have been the product of a successful ligation reaction between the 
pTRKH2 backbone and the human PAH cDNA. LiLi6 appeared to be simply a reconstitution of 
the original pTRKH2 backbone. LiLi8 was an uncharacterized plasmid. Subsequent digests 
revealed that LiLi3 lacked appropriate enzyme cut sites and was thus excluded from further 
experimentation.  
The plasmids LiLi5 and LiLi7 were then each digested in two separate reactions. A single 
digest with Sal1 and a double digest with Sal1 and Sac1were conducted in the manner described 
above. The single digest linearized the plasmids to determine approximate size and the presence 
of appropriate cut sites in the plasmid. The left lanes of Figure 7 show the results of the single 
and double digests, respectively. Double digestion of LiLi5 and LiLi7 revealed that the 1.3 kb 
PAH insert was removed from pTRKH2 backbone, validating that LiLi5 and LiLi7 contained a 
DNA fragment of the correct size and which was excised from plasmid as expected with the 
restriction enzymes corresponding to the ligation sites.  
Additionally of note, LiLi5 and LiLi7 appear to be larger plasmids upon single digest 
with Sal1 when compared to the pTRKH2 single digest with Sal1. This is suggestive that a 
successful ligation had taken place, making the plasmids generated from the ligation larger. 
LiLi5 and LiLi7 were then sent for Sanger sequencing. The read length for LiLi7 was deemed 
too short to be acceptable and it was not further analyzed. As demonstrated by Figure 8, the 
LiLi5 plasmid sequence was aligned with the NCBI sequence for the PAH (NM_000277.2) and 
determined to be 100% identical across the first 716 bases aligned and 99.8% identical across the 
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first 994 bases aligned, which is typically the upper limit of accuracy for standard  Sanger 
sequencing. 
Figure 7 A double restriction enzyme digest was performed to further elucidate the genetic contents of 
the LiLi series of plasmids. The LiLi5 plasmid was subjected to a single digest by Sal1 (high fidelity) and 
is pictured in the lane marked ‘L5 (Sal1HF Digest)’. LiLi5 was also subjected to a double digest with 
Sal1 (high fidelity) and Sac1, the results of which are shown in the lane marked ‘L5 (Double Digest).  As 
shown in the lane marked ‘L5 (Double Digest)’, a fragment is released which is later demonstrated to be 
the PAH insert via Sanger sequencing. LiLi7 and LiLi3 underwent similar digests, as depicted in the ‘L7’ 
and ‘L3’ lanes. pTRHK2 was subjected to a single Sal1 (high fidelity) digest and is shown here in the 
lane marked ‘pTRKH2 (Sal1HF Digest)’. The lane marked “Ladder” is a visualization of the BioRad log2 
ladder.  
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Figure 8 The LiLi5 plasmid was Sanger sequenced and the results were compared to the NCBI reference 
genetic sequence for human PAH (red box). The blue box demonstrates the overall 98% identicality 
between the two sequences. 
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Next, the LiLi5 and pTRKH2 plasmids were transfected separately into Lactobacillus 
helveticus in the manner described in Materials and Methods. pTRKH2 was carried through the 
electroporation as a control to demonstrate positive selection for Lactobacillus helveticus 
containing plasmids yielding erythromycin resistance in liquid culture with antibiotic selection. 
The successful transfection with pTRKH2 and LiLi5 further validated electroporation protocols 
and characterized the behavior of Lactobacillus helveticus post-transfection with plasmid. After 
96 hours, growth in liquid media was noted for cultures undergoing electroporation to introduce 
LiLi5 and pTRKH2 plasmids, suggesting that a plasmid conferring erythromycin resistance had 
successfully been transferred into Lactobacillus helveticus.  
DNA extraction was performed using the Zymo Plasmid MiniPrep kit, per manufacturer 
protocol to further characterize the genetic information of the Lactobacillus helveticus strains 
which presented with erythromycin resistance. A standard PCR reaction was then performed on 
the eluted DNA using primers specific to the PAH cDNA. 
Figure 9 shows the results of the PCR amplification used to confirm the presence of 
LiLi5 in Lactobacillus helveticus. The presence of a band at ~1.3 kb, the identical size to the 
original cDNA isolated from pCMV6-XL4, confirms that the sequence encoding the human 
PAH enzyme is present in the modified Lactobacillus helveticus cells and is not in the pTRKH2 
cells. The new strain of modified Lactobacillus helveticus containing LiLi5 plasmid has been 
christened HELin.  
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Figure 9 The lane marked ‘LiLi5 (LH)’ shows the result of PCR using primers specific to human PAH 
cDNA. This reveals the presence of human PAH cDNA in the genome of L. helveticus. The novel species 
of Lactobacillus that has been created was named HELin. E. coli transfected with the LiLi5 plasmid also 
contained human PAH cDNA as revealed in the lane marked ‘LiLi5 (E. coli)’ after a PCR reaction was 
performed with primers specific to PAH cDNA. As shown in the lanes marked ‘PTRKH2 (LH)’ and 
PTRKH2 (E. coli)’, PCR using primers specific to human PAH cDNA did not yield any DNA 
amplification when perfromed on the pTRKH2 plasmid in either species. 
 
Additional Experimentation 
 Several analyses were performed with the purpose of validating the expression and 
functionality of the full human phenylalanine hydroxylase enzyme in Lactobacillus helveticus 
(HELin). Primarily, a tyrosine assay kit was purchased with the intent to demonstrate that MRS 
media containing HELin had a statistically significant increase in the levels of tyrosine in the 
media. Figure 10 demonstrates the standard curve of tyrosine absorbance across all experiments 
performed.  
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It was hoped that an increase in tyrosine content in MRS media inoculated with HELin 
would be detectable secondary to the production of an exogenous protein metabolizing 
phenylalanine into tyrosine. Unfortunately, despite media deproteinization and concentration 
adjustments, colorimetric analysis of media tyrosine content showed strong inconsistencies in the 
measurement of endogenous levels of tyrosine in control samples, as demonstrated by Figures 
11, 12, and 13. The inconsistencies in the levels of tyrosine in control samples rendered the data 
inconsequential. As the tyrosine content was “trended” over time with timepoint samples at 36, 
48, and 60 hours, there was a confusing inconsistency in both the media inoculated with 
Lactobacillus and the sterile MRS media. The most likely explanation for the failure of the kit to 
provide useful data was interference of the endogenous levels of tyrosine in the MRS broth with 
colorimetric reads of the sample.  
 
Figure 10 A tyrosine standard curve was generated and used throughout all tyrosine assay experiments. 
The enzymatic oxidation of tyrosine produces a stable signal (OD 492 nm), which is directly proportional 
to the amount of Tyr. As the amount of tyrosine in the samples increases, so does the absorbance read. 
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Figure 11 A tyrosine assay was performed three times in order to determine the effect of HELin on the 
local environment. Graphs “A”, “B”, and “C” represent three separate replicates of the tyrosine assay kit. 
Aliquots of the same samples of MRS supernatant were compared in each assay replicate. The blue line 
on the graphs “pTRKH2 (LH)” represents the nM of tyrosine detected in of MRS media inoculated with 
Lactobacillus helveticus transfected with the pTKRH2 plasmid, trended over a period of 60 hours. The 
orange line represents represents the nM of tyrosine detected in of MRS media inoculated with 
Lactobacillus helveticus transfected with the LiLi5 plasmid (HELin), trended over a period of 60 hours. 
The grey line represents represents the nM of tyrosine detected in sterile MRS media trended over a 
period of 60 hours. Interference from endogenous tyrosine levels within MRS broth with no bacteria 
(control media) rendered the data inconsequential. This is demonstrated by the fluctuations in the gray 
lines on the chart. MRS was incubated as a control. As this media was not inoculated with any bacteria, 
the tyrosine levels should have remained constant over time.  
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 Subsequently, Western blotting was attempted to detect the human PAH protein. 
Although an appropriately sized blur is noted for the LiLi5 cell pellet and is absent from the 
pTRKH2 cell pellet, it is not entirely convincing, robust evidence of the presence human 
phenylalanine hydroxylase.  
Figure 12 A Western blot using anti-PAH goat antibody was performed in an attempt to detect the presence 
of the PAH enzyme in Lactobacillus helveticus bacterial pellet or local supernatant. The expected size of the 
PAH protein is ~50 kDa. An appropriately sized blur is seen in the lane marked ‘LiLi5 Cell Pellet’, which is 
suggestive of the fact that the PAH protein may be produced in L. helveticus transfected with LiLi5 (named 
HELin). However, further testing must be done to validate the presence of the fully functional protein. 
Nonspecific binding is also seen across all lanes.  
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The Western blot was repeated with the inclusion of human HCT116 cells as an additonal 
control. Again, an appropriately sized blur is seen in the LiLi5 cell pellet at 36 hours, but is not 
noted in the same cell line at 60 hours, as seen in Figure 13. The lack of a convincing, clearly 
detectable protein at 50 kDa in all LiLi5 samples provided inconclusive evidence of the 
production of the PAH protein. 
 
Figure 13 A second Western blot was performed on samples of Lactobacillus helveticus transfected with 
various plasmids, although it was also inconclusive. Again, an appropriately sized blur was noted at 50 
kDa in the lane marked ‘LiLi5 Cell Pellet 36h’. However, nonspecific binding was, again, also present 
across all lanes. The most nonspecific binding is noted in the additional control lane ‘HCT116 Cas9-
FLAG’. Further investigation into the production of the fully functional PAH protein is warranted, 
perhaps with a more specific alternate antibody. 
  
Discussion and Future Experimental Directions 
The project successfully inserted human cDNA for phenylalanine hydroxylase into a 
GRAS probiotic-type bacterial strain, Lactobacillus helveticus, via the integration of a novel 
plasmid, LiLi5. The creation of HELin represents the first steps toward a pharmabiotic for the 
treatment and mitigation of the metabolic disorder phenylalanine hydroxylase deficiency. 
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  Frustratingly, convincing evidence of successful expression of enzymatically active PAH 
remains lacking.  As stated above, the high endogenous levels of tyrosine in the MRS broth 
likely interfered with colorimetric reads of the sample during the experiments involving the 
tyrosine assay kits. However, it is also possible that PAH was expressed so inefficiently that, had 
the enzyme been successfully hydroxylating phenylalanine, it was doing so to such a small 
degree as to be undetectable. It may be possible to perform more productive experimentation 
utilizing samples with an alternate medium. Experimentation using an alternate medium would 
also be enhanced with additional reading of a phenylalanine level via colorimetric assay.  
 Western blotting procedures could be improved for future experimentation with the 
selection of an alternate, more selective antibody and the inclusion of samples from a wider 
variety of time points. A literature evaluation would need to be performed when choosing a new 
antibody to ensure that the antibody had been used in other successful experiments with bacteria.  
However, problems with enzymatic expression may be deeper, and resistant to changes in 
technical laboratory procedures. Issues with functional expression may, in fact, be secondary to 
differences in codon preferences between species. This problem may be rectified by codon 
optimization. Although it is too early to make definitive conclusions, it is possible that the 
protein was visualized in the Lactobacillus cell pellet at 36 hours because the protein is currently 
expressed intracellularly and sequestered. The phenylalanine hydroxylase may not be visualized 
after 36 hours because the human protein was recognized as foreign and destroyed by 
intracellular proteinases. This provides another opportunity for product optimization.  
Further funding for optimization, characterization, and validation of the functionality of 
HELin has been sought and experimentation is ongoing. 
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Formulation and Administration Considerations 
 Having demonstrated the proof of principle that Lactobacillus helveticus can be 
genetically modified to express the genetic information for human phenylalanine hydroxylase, a 
more completely optimized product would easily lend itself to therapeutic applications. Modified 
L. helveticus can be formulated into a yogurt or capsule and marketed as a medical food or as a 
drug in the United States. Medical foods bypass many of the rigorous examinations conducted by 
the Food and Drug Administration. Although the pathway to market for drugs is more vigorous, 
a pharmabiotic may more closely match the FDA’s definition of a drug as “a substance intended 
for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.” Concentrated care 
would need to be taken by manufacturers to ensure the identity, quality and efficacy of the 
product. The product would likely need to be dispensed on a prescription-only basis, ensuring 
that only appropriately diagnosed patients would receive the product. An anticipated adverse 
effect of inappropriate administration of this product may be muscle weakness due to lack of 
appropriate amounts of phenylalanine used to build proteins.  
Daily dosages of the medical yogurt or capsule would promote stability of plasma 
phenylalanine levels and, depending on the degree of colonization of the gastrointestinal tract, 
may even allow for some dietary variation. The ability to consume foods consistent with the 
general population, even occasionally would be greatly welcomed by the patient population. 
Stability of plasma phenylalanine levels secondary to administration of an optimized HELin 
strain would theoretically reduce the instance of all consequences that appear directly as a result 
of elevated plasma levels or, alternately, as a consequence of therapy-- developmental delays, 
psychosocial deviations, behavioral issues, strange body odor, overweight, and decreased bone 
density. It is likely that multiple administrations per day would be necessary to achieve this type 
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of efficacious bacterial colonization and stability. However, the pill burden would be a small 
grievance compared to the desperation felt by this patient population for a cure, or at least a 
greater sense of normalcy, and is not expected to provide a barrier to market entry.  
The formulation could also be modified into a slurry for inpatient nasogastric 
administration. Nasogastric administration would be ideal for the neonatal phenylketonuric 
population, as use of the entire gastrointestinal tract is certainly considered best practice and this 
method of administration would also allow for immediate colonization after birth. Potentially, 
immediate post-natal administration of such a product would disallow massive fluctuations in 
blood phenylalanine levels, the occurrences most detrimental to psychological development. 
Additionally, nasogastric administration of L. helveticus would be ideal for use in the pregnant 
phenylketonuric population in cases where rapid lowering of blood phenylalanine levels is 
urgent. It has been documented that spikes in the maternal plasma levels of phenylalanine 
damage the developing fetus, with reports of spontaneous abortion, congenital heart failure, and 
psychological developmental delay. Much stress is felt by the pregnant patient population, where 
intense focus must be kept on maintaining low blood phenylalanine levels.8  
Of note, there may be a place in therapy for a pharmabiotic bacterial species maintaining 
antibiotic resistance. Ostensibly, a loading dose of the antibiotic to which the organism is 
resistant could be administered to the patient to, in effect, “clear the way” for the rapid 
proliferation and colonization of the pharmabiotic species. Due to the alarming increase in rate of 
antibiotic resistance in the United States, this strategy should be limited to a one-time loading 
dose and severe cases in which blood phenylalanine levels need to be immediately lowered. As 
with all chemotherapeutics, risks and benefits of treatment strategies must be weighed and 
considered with the holistic clinical picture of the individual patient. 
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Safety concerns surrounding the product would largely be limited to the immune-
suppressed population or those whose inpatient therapy involves a central venous catheter. There 
have been case reports of Lactobacillus bacteremia.27 It is unfortunately expected that these case 
reports will become more frequent as the national focus on the microbiome continues to intensify 
and probiotics become more clinically integrated at the point of care. Intentional external 
administration of bacteria to an immunocompromised patient is clearly contraindicated. Extreme 
caution should be used in the cases of an immunocompetent patient with a central venous 
catheter in place. Additional consideration should be used prior to administration if the patient 
presents with leaky gut syndrome. However, excluding these patient populations, no other safety 
concerns are expected to arise from the administration of such a pharmabiotic.  
Intellectual Property Rights 
 Intellectual property rights were sought for the invention of a pharmabiotic for the 
treatment of phenylalanine hydroxylase deficiency. The provisional patent application was filed 
on December 20, 2018 as ATTY. DOCKET NO.:USC-601-P (1317).  
Forward Projections 
 Phenylalanine hydroxylase deficiency is not the only metabolic disorder that can and 
should be addressed by modification of the microbiome. I predict that the microbiome will 
provide a vast host of resources for the treatment and mitigation of a multitude of disease states. 
Pharmabiotics are the next generation of supportive care and provide a targeted therapeutic with 
minimal risk to the patient. As scientific understanding of the interplay between microbe, host, 
and health expands, exponentially so does the opportunity for ingenuity.  
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Abbreviations  
Ery erythromycin 
HELin L. helveticus containing LiLi5 plasmid 
kb kilobase 
LiLi5 novel plasmid created via ligation of PAH cDNA and pTRKH2 backbone 
mL milliliter 
μL microliter 
ng nanogram 
PAH phenylalanine hydroxylase 
phe phenylalanine  
PKU phenylketonuria 
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Sequences Referenced 
Primer Sequences for PCR of PAH cDNA  
Forward: ATGTCCACTGCGGTCCTGGAAAACCCAGGCTTG 
Reverse: TTACTTTATTTTCTGGAGGGCACTGCAAAGGATTCC 
 
Primer Sequences for PCR of PAH cDNA for the Addition of Sac1 and Sal1 Cut Sites 
Forward (Sac1): CGCGGAGCTCATGTCCACTGCGGTCCTGGAAAACCCAGGCTTG 
Reverse (Sal1): GCGCGTCGACTTACTTTATTTTCTGGAGGGCACTGCAAAGGATTCC 
 
pTRKH2 with Phenylalanine Hydroxylase:  
CCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCAC
GACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTA
GCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGT
GGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGA
ATTCATCGATATCTAGATCTCGAGCTCATGTCCACTGCGGTCCTGGAAAACCCAGGC
TTGGGCAGGAAACTCTCTGACTTTGGACAGGAAACAAGCTATATTGAAGACAACTG
CAATCAAAATGGTGCCATATCACTGATCTTCTCACTCAAAGAAGAAGTTGGTGCATT
GGCCAAAGTATTGCGCTTATTTGAGGAGAATGATGTAAACCTGACCCACATTGAATC
TAGACCTTCTCGTTTAAAGAAAGATGAGTATGAATTTTTCACCCATTTGGATAAACG
TAGCCTGCCTGCTCTGACAAACATCATCAAGATCTTGAGGCATGACATTGGTGCCAC
TGTCCATGAGCTTTCACGAGATAAGAAGAAAGACACAGTGCCCTGGTTCCCAAGAA
CCATTCAAGAGCTGGACAGATTTGCCAATCAGATTCTCAGCTATGGAGCGGAACTGG
ATGCTGACCACCCTGGTTTTAAAGATCCTGTGTACCGTGCAAGACGGAAGCAGTTTG
CTGACATTGCCTACAACTACCGCCATGGGCAGCCCATCCCTCGAGTGGAATACATGG
AGGAAGAAAAGAAAACATGGGGCACAGTGTTCAAGACTCTGAAGTCCTTGTATAAA
ACCCATGCTTGCTATGAGTACAATCACATTTTTCCACTTCTTGAAAAGTACTGTGGCT
TCCATGAAGATAACATTCCCCAGCTGGAAGACGTTTCTCAATTCCTGCAGACTTGCA
CTGGTTTCCGCCTCCGACCTGTGGCTGGCCTGCTTTCCTCTCGGGATTTCTTGGGTGG
CCTGGCCTTCCGAGTCTTCCACTGCACACAGTACATCAGACATGGATCCAAGCCCAT
GTATACCCCCGAACCTGACATCTGCCATGAGCTGTTGGGACATGTGCCCTTGTTTTC
AGATCGCAGCTTTGCCCAGTTTTCCCAGGAAATTGGCCTTGCCTCTCTGGGTGCACCT
GATGAATACATTGAAAAGCTCGCCACAATTTACTGGTTTACTGTGGAGTTTGGGCTC
TGCAAACAAGGAGACTCCATAAAGGCATATGGTGCTGGGCTCCTGTCATCCTTTGGT
GAATTACAGTACTGCTTATCAGAGAAGCCAAAGCTTCTCCCCCTGGAGCTGGAGAA
GACAGCCATCCAAAATTACACTGTCACGGAGTTCCAGCCCCTGTATTACGTGGCAGA
GAGTTTTAATGATGCCAAGGAGAAAGTAAGGAACTTTGCTGCCACAATACCTCGGC
CCTTCTCAGTTCGCTACGACCCATACACCCAAAGGATTGAGGTCTTGGACAATACCC
AGCAGCTTAAGATTTTGGCTGATTCCATTAACAGTGAAATTGGAATCCTTTGCAGTG
46 
 
CCCTCCAGAAAATAAAGTAAGTCGACGGATCCCCGGGAATTCACTGGCCGTCGTTTT
ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACA
TCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA
ACAGTTGCGCAGCCTGAATGGCGAATGCTAGAATCGATACGATTTTGAAGTGGCAA
CAGATAAAAAAAAGCAGTTTAAAATTGTTGCTGAACTTTTAAAACAAGCAAATACA
ATCATTGTCGCAACAGATAGCGACAGAGAAGGCGAAAACATTGCCTGGTCGATCAT
TCATAAAGCAAATGCCTTTTCTAAAGATAAAACGTATAAAAGACTATGGATCAATA
GTTTAGAAAAAGATGTGATCCGTAGCGGTTTTCAAAATTTGCAACCAGGAATGAATT
ACTATCCCTTTTATCAAGAAGCGCAAAAGAAAAACGAAATGATACACCAATCAGTG
CAAAAAAAGATATAATGGGAGATAAGACGGTTCGTGTTCGTGCTGACTTGCACCAT
ATCATAAAAATCGAAACAGCAAAGAATGGCGGAAACGTAAAAGAAGTTATGGAAA
TAAGACTTAGAAGCAAACTTAAGAGTGTGTTGATAGTGCAGTATCTTAAAATTTTGT
ATAATAGGAATTGAAGTTAAATTAGATGCTAAAAATTTGTAATTAAGAAGGAGTGA
TTACATGAACAAAAATATAAAATATTCTCAAAACTTTTTAACGAGTGAAAAAGTACT
CAACCAAATAATAAAACAATTGAATTTAAAAGAAACCGATACCGTTTACGAAATTG
GAACAGGTAAAGGGCATTTAACGACGAAACTGGCTAAAATAAGTAAACAGGTAACG
TCTATTGAATTAGACAGTCATCTATTCAACTTATCGTCAGAAAAATTAAAACTGAAT
ACTCGTGTCACTTTAATTCACCAAGATATTCTACAGTTTCAATTCCCTAACAAACAG
AGGTATAAAATTGTTGGGAGTATTCCTTACCATTTAAGCACACAAATTATTAAAAAA
GTGGTTTTTGAAAGCCATGCGTCTGACATCTATCTGATTGTTGAAGAAGGATTCTAC
AAGCGTACCTTGGATATTCACCGAACACTAGGGTTGCTCTTGCACACTCAAGTCTCG
ATTCAGCAATTGCTTAAGCTGCCAGCGGAATGCTTTCATCCTAAACCAAAAGTAAAC
AGTGTCTTAATAAAACTTACCCGCCATACCACAGATGTTCCAGATAAATATTGGAAG
CTATATACGTACTTTGTTTCAAAATGGGTCAATCGAGAATATCGTCAACTGTTTACTA
AAAATCAGTTTCATCAAGCAATGAAACACGCCAAAGTAAACAATTTAAGTACCGTT
ACTTATGAGCAAGTATTGTCTATTTTTAATAGTTATCTATTATTTAACGGGAGGAAAT
AATTCTATGAGTCGCTTTTGTAAATTTGGAAAGTTACACGTTACTAAAGGGAATGTA
GATAAATTATTAGGTATACTACTGACAGCTTCCAAGGAGCTAAAGAGGTCCCTAGCG
CTCTTATCATGGGGAAGCTCGGATCATATGCAAGACAAAATAAACTCGCAACAGCA
CTTGGAGAAATGGGACGAATCGAGAAAACCCTCTTTACGCTGGATTACATATCTAAT
AAAGCCGTAAGGAGACGGGTTCAAAAAGGTTTAAATAAAGGAGAAGCAATCAATG
CATTAGCTAGAACTATATTTTTTGGACAACGTGGAGAATTTAGAGAACGTGCTCTCC
AAGACCAGTTACAAAGAGCTAGTGCACTAAACATAATTATTAACGCTATAAGTGTGT
GGAACACTGTATATATGGAAAAAGCCGTAGAAGAATTAAAAGCAAGAGGAGAATTT
AGAGAAGATTTAATGCCATATGCGTGGCCGTTAGGATGGGAACATATCAATTTTCTT
GGAGAATACAAATTTGAAGGATTACATGACACTGGGCAAATGAATTTACGTCCTTTA
CGTATAAAAGAGCCGTTTTATTCTTAATATAACGGCTCTTTTTATAGAAAAAATCCTT
AGCGTGGTTTTTTTCCGAAATGCTGGCGGTACCCCAAGAATTAGAAATGAGTAGATC
AAATTATTCACGAATAGAATCAGGAAAATCAGATCCAACCATAAAAACACTAGAAC
AAATTGCAAAGTTAACTAACTCAACGCTAGTAGTGGATTTAATCCCAAATGAGCCAA
CAGAACCAGAGCCAGAAACAGAATCAGAACAAGTAACATTGGATTTAGAAATGGA
AGAAGAAAAAAGCAATGACTTCGTGTGAATAATGCACGAAATCGTTGCTTATTTTTT
TTTAAAAGCGGTATACTAGATATAACGAAACAACGAACTGAATAGAAACGAAAAAA
47 
 
GAGCCATGACACATTTATAAAATGTTTGACGACATTTTATAAATGCATAGCCCGATA
AGATTGCCAAACCAACGCTTATCAGTTAGTCAGATGAACTCTTCCCTCGTAAGAAGT
TATTTAATTAACTTTGTTTGAAGACGGTATATAACCGTACTATCATTATATAGGGAA
ATCAGAGAGTTTTCAAGTATCTAAGCTACTGAATTTAAGAATTGTTAAGCAATCAAT
CGGAAATCGTTTGATTGCTTTTTTTGTATTCATTTATAGAAGGTGGAGTTTGTATGAA
TCATGATGAATGTAAAACTTATATAAAAAATAGTTTATTGGAGATAAGAAAATTAGC
AAATATCTATACACTAGAAACGTTTAAGAAAGAGTTAGAAAAGAGAAATATCTACT
TAGAAACAAAATCAGATAAGTATTTTTCTTCGGAGGGGGAAGATTATATATATAAGT
TAATAGAAAATAACAAAATAATTTATTCGATTAGTGGAAAAAAATTGACTTATAAA
GGAAAAAAATCTTTTTCAAAACATGCAATATTGAAACAGTTGAATGAAAAAGCAAA
CCAAGTTAATTAAACAACCTATTTTATAGGATTTATAGGAAAGGAGAACAGCTGAAT
GAATATCCCTTTTGTTGTAGAAACTGTGCTTCATGACGGCTTGTTAAAGTACAAATTT
AAAAATAGTAAAATTCGCTCAATCACTACCAAGCCAGGTAAAAGCAAAGGGGCTAT
TTTTGCGTATCGCTCAAAATCAAGCATGATTGGCGGTCGTGGTGTTGTTCTGACTTCC
GAGGAAGCGATTCAAGAAAATCAAGATACATTTACACATTGGACACCCAACGTTTA
TCGTTATGGAACGTATGCAGACGAAAACCGTTCATACACGAAAGGACATTCTGAAA
ACAATTTAAGACAAATCAATACCTTCTTTATTGATTTTGATATTCACACGGCAAAAG
AAACTATTTCAGCAAGCGATATTTTAACAACCGCTATTGATTTAGGTTTTATGCCTAC
TATGATTATCAAATCTGATAAAGGTTATCAAGCATATTTTGTTTTAGAAACGCCAGT
CTATGTGACTTCAAAATCAGAATTTAAATCTGTCAAAGCAGCCAAAATAATTTCGCA
AAATATCCGAGAATATTTTGGAAAGTCTTTGCCAGTTGATCTAACGTGTAATCATTTT
GGTATTGCTCGCATACCAAGAACGGACAATGTAGAATTTTTTGATCCTAATTACCGT
TATTCTTTCAAAGAATGGCAAGATTGGTCTTTCAAACAAACAGATAATAAGGGCTTT
ACTCGTTCAAGTCTAACGGTTTTAAGCGGTACAGAAGGCAAAAAACAAGTAGATGA
ACCCTGGTTTAATCTCTTATTGCACGAAACGAAATTTTCAGGAGAAAAGGGTTTAAT
AGGGCGTAATAACGTCATGTTTACCCTCTCTTTAGCCTACTTTAGTTCAGGCTATTCA
ATCGAAACGTGCGAATATAATATGTTTGAGTTTAATAATCGATTAGATCAACCCTTA
GAAGAAAAAGAAGTAATCAAAATTGTTAGAAGTGCCTATTCAGAAAACTATCAAGG
GGCTAATAGGGAATACATTACCATTCTTTGCAAAGCTTGGGTATCAAGTGATTTAAC
CAGTAAAGATTTATTTGTCCGTCAAGGGTGGTTTAAATTCAAGAAAAAAAGAAGCG
AACGTCAACGTGTTCATTTGTCAGAATGGAAAGAAGATTTAATGGCTTATATTAGCG
AAAAAAGCGATGTATACAAGCCTTATTTAGTGACGACCAAAAAAGAGATTAGAGAA
GTGCTAGGCATTCCTGAACGGACATTAGATAAATTGCTGAAGGTACTGAAGGCGAA
TCAGGAAATTTTCTTTAAGATTAAACCAGGAAGAAATGGTGGCATTCAACTTGCTAG
TGTTAAATCATTGTTGCTATCGATCATTAAAGTAAAAAAAGAAGAAAAAGAAAGCT
ATATAAAGGCGCTGACAAATTCTTTTGACTTAGAGCATACATTCATTCAAGAGACTT
TAAACAAGCTAGCAGAACGCCCTAAAACGGACACACAACTCGATTTGTTTAGCTAT
GATACAGGCTGAAAATAAAACCCGCACTATGCCATTACATTTATATCTATGATACGT
GTTTGTTTTTTCTTTGCTGTTTAGCGAATGATTAGCAGAAATATACAGAGTAAGATTT
TAATTAATTATTAGGGGGAGAAGGAGAGAGTAGCCCGAAAACTTTTAGTTGGCTTG
GACTGAACGAAGTGAGGGAAAGGCTACTAAAACGTCGAGGGGCAGTGAGAGCGAA
GCGAACACTTGATTTTTTAATTTTCTATCTTTTATAGGTCATTAGAGTATACTTATTTG
TCCTATAAACTATTTAGCAGCATAATAGATTTATTGAATAGGTCATTTAAGTTGAGC
48 
 
ATATTAGAGGAGGAAAATCTTGGAGAAATATTTGAAGAACCCGATTACATGGATTG
GATTAGTTCTTGTGGTTACGTGGTTTTTAACTAAAAGTAGTGAATTTTTGATTTTTGG
TGTGTGTGTCTTGTTGTTAGTATTTGCTAGTCAAAGTGATTAAATAGAATTCCGGATG
AGCATTCATCAGGCGGGCAAGAATGTGAATAAAGGCCGGATAAAACTTGTGCTTAT
TTTTCTTTACGGTCTTTAAAAAGGCCGTAATATCCAGCTGAACGGTCTGGTTATAGGT
ACATTGAGCAACTGACTGAAATGCCTCAAAATGTTCTTTACGATGCCATTGGGATAT
ATCAACGGTGGTATATCCAGTGATTTTTTTCTCCATTTTAGCTTCCTTAGCTCCTGAA
AATCTCGATAACTCAAAAAATACGCCCGGTAGTGATCTTATTTCATTATGGTGAAAG
TTGGAACCTCTTACGTGCCGATCAACGTCTCATTTTCGCCAAAAGTTGGCCCAGGGC
TTCCCGGTATCAACAGGGACACCAGGATTTATTTATTCTGCGAAGTGATCTTCCGTC
ACAGGTATTTATTCGGCGCAAAGTGCGTCGGGTGATGCTGCCAACTTACTGATTTAG
TGTATGATGGTGTTTTTGAGGTGCTCCAGTGGCTTCTGTTTCTATCAGCTGTCCCTCC
TGTTCAGCTACTGACGGGGTGGTGCGTAACGGCAAAAGCACCGCCGGACATCAGCG
CTAGCGGAGTGTATACTGGCTTACTATGTTGGCACTGATGAGGGTGTCAGTGAAGTG
CTTCATGTGGCAGGAGAAAAAAGGCTGCACCGGTGCGTCAGCAGAATATGTGATAC
AGGATATATTCCGCTTCCTCGCTCACTGACTCGCTACGCTCGGTCGTTCGACTGCGG
CGAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCCTGGAAGATGCCAGGAAGAT
ACTTAACAGGGAAGTGAGAGGGCCGCGGCAAAGCCGTTTTTCCATAGGCTCCGCCC
CCCTGACAAGCATCACGAAATCTGACGCTCAAATCAGTGGTGGCGAAACCCGACAG
GACTATAAAGATACCAGGCGTTTCCCCCTGGCGGCTCCCTCGTGCGCTCTCCTGTTC
CTGCCTTTCGGTTTACCGGTGTCATTCCGCTGTTATGGCCGCGTTTGTCTCATTCCAC
GCCTGACACTCAGTTCCGGGTAGGCAGTTCGCTCCAAGCTGGACTGTATGCACGAAC
CCCCCGTTCAGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACC
CGGAAAGACATGCAAAAGCACCACTGGCAGCAGCCACTGGTAATTGATTTAGAGGA
GTTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTGGTGA
CTGCGCTCCTCCAAGCCAGTTACCTCGGTTCAAAGAGTTGGTAGCTCAGAGAACCTT
CGAAAAACCGCCCTGCAAGGCGGTTTTTTCGTTTTCAGAGCAAGAGATTACGCGCAG
ACCAAAACGATCTCAAGAAGATCATCTTATTAATCAGATAAAATATTTCTAG 
 
Phenylalanine Hydroxylase Insert with Enzyme Cut Sites: 
CGCGGAGCTCATGTCCACTGCGGTCCTGGAAAACCCAGGCTTGGGCAGGAAACTCT
CTGACTTTGGACAGGAAACAAGCTATATTGAAGACAACTGCAATCAAAATGGTGCC
ATATCACTGATCTTCTCACTCAAAGAAGAAGTTGGTGCATTGGCCAAAGTATTGCGC
TTATTTGAGGAGAATGATGTAAACCTGACCCACATTGAATCTAGACCTTCTCGTTTA
AAGAAAGATGAGTATGAATTTTTCACCCATTTGGATAAACGTAGCCTGCCTGCTCTG
ACAAACATCATCAAGATCTTGAGGCATGACATTGGTGCCACTGTCCATGAGCTTTCA
CGAGATAAGAAGAAAGACACAGTGCCCTGGTTCCCAAGAACCATTCAAGAGCTGGA
CAGATTTGCCAATCAGATTCTCAGCTATGGAGCGGAACTGGATGCTGACCACCCTGG
TTTTAAAGATCCTGTGTACCGTGCAAGACGGAAGCAGTTTGCTGACATTGCCTACAA
CTACCGCCATGGGCAGCCCATCCCTCGAGTGGAATACATGGAGGAAGAAAAGAAAA
CATGGGGCACAGTGTTCAAGACTCTGAAGTCCTTGTATAAAACCCATGCTTGCTATG
49 
 
AGTACAATCACATTTTTCCACTTCTTGAAAAGTACTGTGGCTTCCATGAAGATAACA
TTCCCCAGCTGGAAGACGTTTCTCAATTCCTGCAGACTTGCACTGGTTTCCGCCTCCG
ACCTGTGGCTGGCCTGCTTTCCTCTCGGGATTTCTTGGGTGGCCTGGCCTTCCGAGTC
TTCCACTGCACACAGTACATCAGACATGGATCCAAGCCCATGTATACCCCCGAACCT
GACATCTGCCATGAGCTGTTGGGACATGTGCCCTTGTTTTCAGATCGCAGCTTTGCCC
AGTTTTCCCAGGAAATTGGCCTTGCCTCTCTGGGTGCACCTGATGAATACATTGAAA
AGCTCGCCACAATTTACTGGTTTACTGTGGAGTTTGGGCTCTGCAAACAAGGAGACT
CCATAAAGGCATATGGTGCTGGGCTCCTGTCATCCTTTGGTGAATTACAGTACTGCT
TATCAGAGAAGCCAAAGCTTCTCCCCCTGGAGCTGGAGAAGACAGCCATCCAAAAT
TACACTGTCACGGAGTTCCAGCCCCTGTATTACGTGGCAGAGAGTTTTAATGATGCC
AAGGAGAAAGTAAGGAACTTTGCTGCCACAATACCTCGGCCCTTCTCAGTTCGCTAC
GACCCATACACCCAAAGGATTGAGGTCTTGGACAATACCCAGCAGCTTAAGATTTTG
GCTGATTCCATTAACAGTGAAATTGGAATCCTTTGCAGTGCCCTCCAGAAAATAAAG
TAAGTCGACGCGC 
 
pTRKH2 Sequence:  
CCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCAC
GACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTA
GCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGT
GGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGA
ATTCATCGATATCTAGATCTCGAGCTCGCGAAAGCTTGGCTGCAGGTCGACGGATCC
CCGGGAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTA
CCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAG
AGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGCTAG
AATCGATACGATTTTGAAGTGGCAACAGATAAAAAAAAGCAGTTTAAAATTGTTGC
TGAACTTTTAAAACAAGCAAATACAATCATTGTCGCAACAGATAGCGACAGAGAAG
GCGAAAACATTGCCTGGTCGATCATTCATAAAGCAAATGCCTTTTCTAAAGATAAAA
CGTATAAAAGACTATGGATCAATAGTTTAGAAAAAGATGTGATCCGTAGCGGTTTTC
AAAATTTGCAACCAGGAATGAATTACTATCCCTTTTATCAAGAAGCGCAAAAGAAA
AACGAAATGATACACCAATCAGTGCAAAAAAAGATATAATGGGAGATAAGACGGTT
CGTGTTCGTGCTGACTTGCACCATATCATAAAAATCGAAACAGCAAAGAATGGCGG
AAACGTAAAAGAAGTTATGGAAATAAGACTTAGAAGCAAACTTAAGAGTGTGTTGA
TAGTGCAGTATCTTAAAATTTTGTATAATAGGAATTGAAGTTAAATTAGATGCTAAA
AATTTGTAATTAAGAAGGAGTGATTACATGAACAAAAATATAAAATATTCTCAAAA
CTTTTTAACGAGTGAAAAAGTACTCAACCAAATAATAAAACAATTGAATTTAAAAG
AAACCGATACCGTTTACGAAATTGGAACAGGTAAAGGGCATTTAACGACGAAACTG
GCTAAAATAAGTAAACAGGTAACGTCTATTGAATTAGACAGTCATCTATTCAACTTA
TCGTCAGAAAAATTAAAACTGAATACTCGTGTCACTTTAATTCACCAAGATATTCTA
CAGTTTCAATTCCCTAACAAACAGAGGTATAAAATTGTTGGGAGTATTCCTTACCAT
TTAAGCACACAAATTATTAAAAAAGTGGTTTTTGAAAGCCATGCGTCTGACATCTAT
CTGATTGTTGAAGAAGGATTCTACAAGCGTACCTTGGATATTCACCGAACACTAGGG
50 
 
TTGCTCTTGCACACTCAAGTCTCGATTCAGCAATTGCTTAAGCTGCCAGCGGAATGC
TTTCATCCTAAACCAAAAGTAAACAGTGTCTTAATAAAACTTACCCGCCATACCACA
GATGTTCCAGATAAATATTGGAAGCTATATACGTACTTTGTTTCAAAATGGGTCAAT
CGAGAATATCGTCAACTGTTTACTAAAAATCAGTTTCATCAAGCAATGAAACACGCC
AAAGTAAACAATTTAAGTACCGTTACTTATGAGCAAGTATTGTCTATTTTTAATAGTT
ATCTATTATTTAACGGGAGGAAATAATTCTATGAGTCGCTTTTGTAAATTTGGAAAG
TTACACGTTACTAAAGGGAATGTAGATAAATTATTAGGTATACTACTGACAGCTTCC
AAGGAGCTAAAGAGGTCCCTAGCGCTCTTATCATGGGGAAGCTCGGATCATATGCA
AGACAAAATAAACTCGCAACAGCACTTGGAGAAATGGGACGAATCGAGAAAACCCT
CTTTACGCTGGATTACATATCTAATAAAGCCGTAAGGAGACGGGTTCAAAAAGGTTT
AAATAAAGGAGAAGCAATCAATGCATTAGCTAGAACTATATTTTTTGGACAACGTG
GAGAATTTAGAGAACGTGCTCTCCAAGACCAGTTACAAAGAGCTAGTGCACTAAAC
ATAATTATTAACGCTATAAGTGTGTGGAACACTGTATATATGGAAAAAGCCGTAGA
AGAATTAAAAGCAAGAGGAGAATTTAGAGAAGATTTAATGCCATATGCGTGGCCGT
TAGGATGGGAACATATCAATTTTCTTGGAGAATACAAATTTGAAGGATTACATGACA
CTGGGCAAATGAATTTACGTCCTTTACGTATAAAAGAGCCGTTTTATTCTTAATATA
ACGGCTCTTTTTATAGAAAAAATCCTTAGCGTGGTTTTTTTCCGAAATGCTGGCGGTA
CCCCAAGAATTAGAAATGAGTAGATCAAATTATTCACGAATAGAATCAGGAAAATC
AGATCCAACCATAAAAACACTAGAACAAATTGCAAAGTTAACTAACTCAACGCTAG
TAGTGGATTTAATCCCAAATGAGCCAACAGAACCAGAGCCAGAAACAGAATCAGAA
CAAGTAACATTGGATTTAGAAATGGAAGAAGAAAAAAGCAATGACTTCGTGTGAAT
AATGCACGAAATCGTTGCTTATTTTTTTTTAAAAGCGGTATACTAGATATAACGAAA
CAACGAACTGAATAGAAACGAAAAAAGAGCCATGACACATTTATAAAATGTTTGAC
GACATTTTATAAATGCATAGCCCGATAAGATTGCCAAACCAACGCTTATCAGTTAGT
CAGATGAACTCTTCCCTCGTAAGAAGTTATTTAATTAACTTTGTTTGAAGACGGTAT
ATAACCGTACTATCATTATATAGGGAAATCAGAGAGTTTTCAAGTATCTAAGCTACT
GAATTTAAGAATTGTTAAGCAATCAATCGGAAATCGTTTGATTGCTTTTTTTGTATTC
ATTTATAGAAGGTGGAGTTTGTATGAATCATGATGAATGTAAAACTTATATAAAAAA
TAGTTTATTGGAGATAAGAAAATTAGCAAATATCTATACACTAGAAACGTTTAAGAA
AGAGTTAGAAAAGAGAAATATCTACTTAGAAACAAAATCAGATAAGTATTTTTCTTC
GGAGGGGGAAGATTATATATATAAGTTAATAGAAAATAACAAAATAATTTATTCGA
TTAGTGGAAAAAAATTGACTTATAAAGGAAAAAAATCTTTTTCAAAACATGCAATAT
TGAAACAGTTGAATGAAAAAGCAAACCAAGTTAATTAAACAACCTATTTTATAGGA
TTTATAGGAAAGGAGAACAGCTGAATGAATATCCCTTTTGTTGTAGAAACTGTGCTT
CATGACGGCTTGTTAAAGTACAAATTTAAAAATAGTAAAATTCGCTCAATCACTACC
AAGCCAGGTAAAAGCAAAGGGGCTATTTTTGCGTATCGCTCAAAATCAAGCATGAT
TGGCGGTCGTGGTGTTGTTCTGACTTCCGAGGAAGCGATTCAAGAAAATCAAGATAC
ATTTACACATTGGACACCCAACGTTTATCGTTATGGAACGTATGCAGACGAAAACCG
TTCATACACGAAAGGACATTCTGAAAACAATTTAAGACAAATCAATACCTTCTTTAT
TGATTTTGATATTCACACGGCAAAAGAAACTATTTCAGCAAGCGATATTTTAACAAC
CGCTATTGATTTAGGTTTTATGCCTACTATGATTATCAAATCTGATAAAGGTTATCAA
GCATATTTTGTTTTAGAAACGCCAGTCTATGTGACTTCAAAATCAGAATTTAAATCT
GTCAAAGCAGCCAAAATAATTTCGCAAAATATCCGAGAATATTTTGGAAAGTCTTTG
51 
 
CCAGTTGATCTAACGTGTAATCATTTTGGTATTGCTCGCATACCAAGAACGGACAAT
GTAGAATTTTTTGATCCTAATTACCGTTATTCTTTCAAAGAATGGCAAGATTGGTCTT
TCAAACAAACAGATAATAAGGGCTTTACTCGTTCAAGTCTAACGGTTTTAAGCGGTA
CAGAAGGCAAAAAACAAGTAGATGAACCCTGGTTTAATCTCTTATTGCACGAAACG
AAATTTTCAGGAGAAAAGGGTTTAATAGGGCGTAATAACGTCATGTTTACCCTCTCT
TTAGCCTACTTTAGTTCAGGCTATTCAATCGAAACGTGCGAATATAATATGTTTGAG
TTTAATAATCGATTAGATCAACCCTTAGAAGAAAAAGAAGTAATCAAAATTGTTAG
AAGTGCCTATTCAGAAAACTATCAAGGGGCTAATAGGGAATACATTACCATTCTTTG
CAAAGCTTGGGTATCAAGTGATTTAACCAGTAAAGATTTATTTGTCCGTCAAGGGTG
GTTTAAATTCAAGAAAAAAAGAAGCGAACGTCAACGTGTTCATTTGTCAGAATGGA
AAGAAGATTTAATGGCTTATATTAGCGAAAAAAGCGATGTATACAAGCCTTATTTAG
TGACGACCAAAAAAGAGATTAGAGAAGTGCTAGGCATTCCTGAACGGACATTAGAT
AAATTGCTGAAGGTACTGAAGGCGAATCAGGAAATTTTCTTTAAGATTAAACCAGG
AAGAAATGGTGGCATTCAACTTGCTAGTGTTAAATCATTGTTGCTATCGATCATTAA
AGTAAAAAAAGAAGAAAAAGAAAGCTATATAAAGGCGCTGACAAATTCTTTTGACT
TAGAGCATACATTCATTCAAGAGACTTTAAACAAGCTAGCAGAACGCCCTAAAACG
GACACACAACTCGATTTGTTTAGCTATGATACAGGCTGAAAATAAAACCCGCACTAT
GCCATTACATTTATATCTATGATACGTGTTTGTTTTTTCTTTGCTGTTTAGCGAATGAT
TAGCAGAAATATACAGAGTAAGATTTTAATTAATTATTAGGGGGAGAAGGAGAGAG
TAGCCCGAAAACTTTTAGTTGGCTTGGACTGAACGAAGTGAGGGAAAGGCTACTAA
AACGTCGAGGGGCAGTGAGAGCGAAGCGAACACTTGATTTTTTAATTTTCTATCTTT
TATAGGTCATTAGAGTATACTTATTTGTCCTATAAACTATTTAGCAGCATAATAGATT
TATTGAATAGGTCATTTAAGTTGAGCATATTAGAGGAGGAAAATCTTGGAGAAATAT
TTGAAGAACCCGATTACATGGATTGGATTAGTTCTTGTGGTTACGTGGTTTTTAACTA
AAAGTAGTGAATTTTTGATTTTTGGTGTGTGTGTCTTGTTGTTAGTATTTGCTAGTCA
AAGTGATTAAATAGAATTCCGGATGAGCATTCATCAGGCGGGCAAGAATGTGAATA
AAGGCCGGATAAAACTTGTGCTTATTTTTCTTTACGGTCTTTAAAAAGGCCGTAATA
TCCAGCTGAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCTCAAAA
TGTTCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTTCT
CCATTTTAGCTTCCTTAGCTCCTGAAAATCTCGATAACTCAAAAAATACGCCCGGTA
GTGATCTTATTTCATTATGGTGAAAGTTGGAACCTCTTACGTGCCGATCAACGTCTCA
TTTTCGCCAAAAGTTGGCCCAGGGCTTCCCGGTATCAACAGGGACACCAGGATTTAT
TTATTCTGCGAAGTGATCTTCCGTCACAGGTATTTATTCGGCGCAAAGTGCGTCGGG
TGATGCTGCCAACTTACTGATTTAGTGTATGATGGTGTTTTTGAGGTGCTCCAGTGGC
TTCTGTTTCTATCAGCTGTCCCTCCTGTTCAGCTACTGACGGGGTGGTGCGTAACGGC
AAAAGCACCGCCGGACATCAGCGCTAGCGGAGTGTATACTGGCTTACTATGTTGGC
ACTGATGAGGGTGTCAGTGAAGTGCTTCATGTGGCAGGAGAAAAAAGGCTGCACCG
GTGCGTCAGCAGAATATGTGATACAGGATATATTCCGCTTCCTCGCTCACTGACTCG
CTACGCTCGGTCGTTCGACTGCGGCGAGCGGAAATGGCTTACGAACGGGGCGGAGA
TTTCCTGGAAGATGCCAGGAAGATACTTAACAGGGAAGTGAGAGGGCCGCGGCAAA
GCCGTTTTTCCATAGGCTCCGCCCCCCTGACAAGCATCACGAAATCTGACGCTCAAA
TCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGCG
GCTCCCTCGTGCGCTCTCCTGTTCCTGCCTTTCGGTTTACCGGTGTCATTCCGCTGTTA
52 
 
TGGCCGCGTTTGTCTCATTCCACGCCTGACACTCAGTTCCGGGTAGGCAGTTCGCTC
CAAGCTGGACTGTATGCACGAACCCCCCGTTCAGTCCGACCGCTGCGCCTTATCCGG
TAACTATCGTCTTGAGTCCAACCCGGAAAGACATGCAAAAGCACCACTGGCAGCAG
CCACTGGTAATTGATTTAGAGGAGTTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAA
ACTGAAAGGACAAGTTTTGGTGACTGCGCTCCTCCAAGCCAGTTACCTCGGTTCAAA
GAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTCGTTT
TCAGAGCAAGAGATTACGCGCAGACCAAAACGATCTCAAGAAGATCATCTTATTAA
TCAGATAAAATATTTCTAG 
 
